By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced it has received clearance from the US Food and Drug Administration to market its Xpert SA Nasal Complete.

The test is the only molecular diagnostic product designed for the detection and differentiation of Staphylococcus aureas and Methicillin-resistant Staphylococccus aureus colonization in under one hour, Cepheid said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.